Companion Diagnostics Market Overview
The global healthcare industry is witnessing a major transformation with the rapid adoption of precision medicine, where treatments are tailored according to an individual’s genetic profile and disease characteristics. At the heart of this revolution lies companion diagnostics (CDx)—specialized diagnostic tests that help determine whether a patient is likely to benefit from a particular therapy.
According to recent market research, the Companion Diagnostics Market is projected to grow from USD 6.31 billion in 2026 to USD 11.57 billion by 2031, registering a compound annual growth rate (CAGR) of 12.9%. The market’s expansion is fueled by increasing demand for targeted therapies, rising biomarker testing, advances in molecular diagnostics, and stronger collaboration between pharmaceutical and diagnostic companies.
As personalized healthcare becomes the new standard, companion diagnostics are expected to play an even more critical role in improving treatment outcomes while reducing unnecessary healthcare costs.
What Are Companion Diagnostics?
Companion diagnostics are medical devices or laboratory tests that provide essential information for the safe and effective use of a specific therapeutic drug. These tests identify biomarkers, genetic mutations, or protein expressions that determine whether a patient is eligible for a targeted treatment.
Unlike traditional diagnostic tests, companion diagnostics directly influence treatment decisions by helping physicians:
- Identify patients most likely to respond to a therapy
- Avoid ineffective treatments
- Minimize adverse drug reactions
- Improve clinical outcomes
- Support personalized treatment strategies
The increasing integration of diagnostics with therapeutic development has made companion diagnostics an indispensable component of modern oncology and precision medicine.
Key Factors Driving Market Growth
Growing Adoption of Precision Medicine
Healthcare is moving away from the traditional “one-size-fits-all” treatment model toward personalized therapies. Precision medicine relies heavily on companion diagnostics to identify patient populations that can benefit from targeted drugs, making CDx an essential part of clinical decision-making.
Increasing Use of Targeted Therapies
The pharmaceutical industry continues to develop targeted therapies for various diseases, particularly cancer. Most of these therapies require biomarker testing before treatment begins, creating strong demand for companion diagnostic tests.
Expansion of Oncology Biomarker Testing
Cancer treatment has become increasingly dependent on molecular profiling and biomarker identification. Tests for biomarkers such as EGFR, HER2, ALK, KRAS, and PD-L1 have become routine in many cancer treatment protocols, driving market growth.
Rising Drug–Diagnostic Co-development
Pharmaceutical and diagnostic companies are increasingly collaborating during drug development to create companion diagnostics alongside new therapies. This integrated approach improves regulatory approval rates while ensuring better patient selection during clinical trials.
PCR Continues to Dominate Technology Segment
Among various technologies used in companion diagnostics, Polymerase Chain Reaction (PCR) held a significant market share in 2025.
PCR remains one of the most widely adopted technologies due to its:
- High analytical sensitivity
- Fast turnaround time
- Established regulatory acceptance
- Cost-effectiveness
- Broad applicability in mutation detection
PCR-based assays continue to be widely used for detecting genetic mutations associated with targeted therapies across multiple disease areas.
Next-Generation Sequencing (NGS) to Witness Fastest Growth
Although PCR currently dominates the market, Next-Generation Sequencing (NGS) is expected to register the fastest growth during the forecast period.
NGS enables comprehensive genomic profiling by simultaneously analyzing hundreds or thousands of genes, making it highly valuable in precision oncology.
Growing adoption of NGS is being driven by:
- Multi-gene panel testing
- Comprehensive genomic profiling
- Declining sequencing costs
- Improved clinical utility
- Increasing availability of precision oncology programs
As healthcare providers seek more comprehensive genomic insights, NGS is expected to become increasingly important in companion diagnostic testing.
Cancer Remains the Largest Application Area
Cancer represented the leading indication segment in the companion diagnostics market in 2025.
The dominance of oncology is not surprising, considering that the majority of approved companion diagnostic tests are linked to cancer therapies.
Several factors continue to support this leadership:
- Rising global cancer incidence
- Growing approvals of targeted therapies
- Expansion of immunotherapy treatments
- Increased biomarker-driven clinical decision-making
- Improved access to molecular diagnostic testing
Companion diagnostics have become standard practice for several cancers, including:
- Breast cancer
- Lung cancer
- Colorectal cancer
- Melanoma
- Ovarian cancer
Beyond oncology, companion diagnostics are gradually expanding into cardiovascular diseases, infectious diseases, autoimmune disorders, and neurological conditions, creating additional growth opportunities.
North America Leads the Global Market
North America accounted for the largest share of the global companion diagnostics market in 2025.
Several factors contribute to the region’s leadership:
- Strong adoption of precision medicine
- Advanced molecular diagnostic infrastructure
- Favorable regulatory environment
- High healthcare expenditure
- Significant investments in cancer research
- Presence of major pharmaceutical and diagnostic companies
The United States continues to lead innovation in companion diagnostics through strong collaboration among biotechnology firms, pharmaceutical manufacturers, research institutions, and regulatory agencies.
Asia Pacific Emerging as the Fastest-Growing Region
While North America currently dominates the market, the Asia Pacific region is expected to experience the highest growth rate during the forecast period.
Growth is being supported by:
- Increasing healthcare investments
- Expanding cancer screening programs
- Rising adoption of molecular diagnostics
- Growing awareness of personalized medicine
- Improved access to genomic testing
- Expansion of pharmaceutical manufacturing
Countries such as China, Japan, India, and South Korea are investing heavily in precision medicine initiatives, creating attractive opportunities for market participants.
Competitive Landscape
The companion diagnostics market is highly competitive, with global diagnostic companies, pharmaceutical manufacturers, biotechnology firms, and genomic testing specialists continuously investing in research, product development, and strategic collaborations.
Major companies operating in the market include:
- F. Hoffmann-La Roche AG
- Agilent Technologies
- QIAGEN
- Thermo Fisher Scientific
- Guardant Health
- Danaher
- Abbott
- Illumina
- Almac Group
- bioMérieux
- Myriad Genetics
- Sysmex Corporation
- ARUP Laboratories
- ICON Plc
- Quest Diagnostics
- Amoy Diagnostics
- Tempus AI
- Caris Life Sciences
- Abnova Corporation
- Invivoscribe Technologies
- Q2 Solutions
- Pillar Biosciences
- Creative Biolabs
- EntroGen
- Biocartis
These companies continue to strengthen their market positions through acquisitions, strategic partnerships, biomarker discovery programs, regulatory approvals, and investments in advanced genomic technologies.
Future Outlook
The future of companion diagnostics looks exceptionally promising as healthcare increasingly embraces personalized treatment approaches. Advances in artificial intelligence, bioinformatics, liquid biopsy technologies, and comprehensive genomic profiling are expected to further enhance diagnostic accuracy and clinical utility.
With pharmaceutical companies developing an expanding pipeline of targeted therapies, the demand for reliable companion diagnostic tests will continue to rise. Additionally, regulatory agencies worldwide are encouraging the integration of diagnostics into drug development, accelerating market adoption.
As precision medicine becomes the standard of care across oncology and other therapeutic areas, companion diagnostics will remain a cornerstone of modern healthcare, enabling clinicians to deliver safer, more effective, and highly personalized treatments.
Conclusion
The global companion diagnostics market is entering a period of sustained growth, supported by technological innovation, increasing biomarker testing, expanding precision medicine initiatives, and the rapid development of targeted therapies. Projected to reach USD 11.57 billion by 2031, the market represents one of the fastest-growing segments within molecular diagnostics.
As healthcare systems continue to prioritize personalized treatment strategies, companion diagnostics will play an increasingly vital role in improving patient outcomes, optimizing therapeutic effectiveness, and shaping the future of precision medicine worldwide.